Wen Zhang

Dr. Wen Zhang

Cancer Hospital of Chinese Academy of Medical Sciences, Beijing, China

Research Focus & Metrics

Academic Career Length

21Years (2006-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 July 2023 in Nature Reviews Immunology
Verified
Journal Article
Closed access
PDF file
ZZZhenzhen Zhou
Zhenzhen Zhou
Yuan PangYuan Pang
Yuan Pang
JJJingyuan Ji
Jingyuan Ji
JHJianyu He
Jianyu He
TLTiankun Liu
Tiankun Liu
WSWei Sun
Wei Sun

1 May 2014 in Journal of Ethnopharmacology
Verified
Journal Article
Closed access
Guohua WangGuohua Wang
Guohua Wang
RLRui Lan
Rui Lan
XZXin-De Zhen
Xin-De Zhen
WZWen Zhang
Wen Zhang
JXJun Xiang
Jun Xiang
DCDingfang Cai
Dingfang Cai

17 December 2023 in Cancer Innovation
Verified
Journal Article
Open access
ZGZhaoru Gu
Zhaoru Gu
QWQuanyou Wu
Quanyou Wu
BSBingqing Shang
Bingqing Shang
KZKaitai Zhang
Kaitai Zhang
WZWen Zhang
Wen Zhang
In recent years, the three‐dimensional (3D) culture system has emerged as a promising preclinical model for tumor research owing to its ability to replicate the tissue structure and molecular characteristics of solid tumors in vivo. This system offers several advantages, including high throughput, efficiency, and retention of tumor heterogeneity. Traditional Matrigel‐submerged organoid cultures primarily support the long‐term proliferation of epithelial cells. One solution for the exploration of the tumor microenvironment is a reconstitution approach involving the introduction of exogenous cell types, either in dual, triple or even multiple combinations. Another solution is a holistic approach including patient‐derived tumor fragments, air‐liquid interface, suspension 3D culture, and microfluidic tumor‐on‐chip models. Organoid co‐culture models have also gained popularity for studying the tumor microenvironment, evaluating tumor immunotherapy, identifying predictive biomarkers, screening for effective drugs, and modeling infections. By leveraging these 3D culture systems, it is hoped to advance the clinical application of therapeutic approaches and improve patient outcomes.

10 January 2022 in Cell Death Discovery
Verified
Journal Article
Open access
PDF file
LZLulin Zhou
Lulin Zhou
ZNZubiao Niu
Zubiao Niu
YWYuqi Wang
Yuqi Wang
YZYou Zheng
You Zheng
YZYichao Zhu
Yichao Zhu
QSQiang Sun
Qiang Sun
Senescence is believed to be a pivotal player in the onset and progression of tumors as well as cancer therapy. However, the guiding roles of senescence in clinical outcomes and therapy selection for patients with cancer remain obscure, largely due to the absence of a feasible senescence signature. Here, by integrative analysis of single cell and bulk transcriptome data from multiple datasets of gastric cancer patients, we uncovered senescence as a veiled tumor feature characterized by senescence gene signature enriched, unexpectedly, in the noncancerous cells, and further identified two distinct senescence-associated subtypes based on the unsupervised clustering. Patients with the senescence subtype had higher tumor mutation loads and better prognosis as compared with the aggressive subtype. By the machine learning, we constructed a scoring system termed as senescore based on six signature genes: ADH1B, IL1A, SERPINE1, SPARC, EZH2, and TNFAIP2. Higher senescore demonstrated robustly predictive capability for longer overall and recurrence-free survival in 2290 gastric cancer samples, which was independently validated by the multiplex staining analysis of gastric cancer samples on the tissue microarray. Remarkably, the senescore signature served as a reliable predictor of chemotherapeutic and immunotherapeutic efficacies, with high-senescore patients benefited from immunotherapy, while low-senescore patients were responsive to chemotherapy. Collectively, we report senescence as a heretofore unrecognized hallmark of gastric cancer that impacts patient outcomes and therapeutic efficacy.

18 May 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
WZWen Zhang
Wen Zhang
LBLi Bao
Li Bao
SYShaoxing Yang
Shaoxing Yang
ZQZhaoyang Qian
Zhaoyang Qian
MDMei Dong
Mei Dong
SCShujun Cheng
Shujun Cheng
Tumor-selective replication herpes simplex virus-based technology significantly improves clinical detection and prognostication of viable circulating tumor cells Tumor-selective replication herpes simplex virus-based technology significantly improves clinical detection and prognostication of viable circulating tumor cells

8 June 2021 in JCI Insight
Verified
Journal Article
Open access
PDF file
WZWen Zhang
Wen Zhang
XDXinchun Duan
Xinchun Duan
ZZZhenrong Zhang
Zhenrong Zhang
ZYzhenrong yang
zhenrong yang
CZChangyun Zhao
Changyun Zhao
KZKaitai Zhang
Kaitai Zhang
BACKGROUND: Early diagnosis and treatment are key to the long-term survival of lung cancer patients. Although CT has significantly contributed to the early diagnosis of lung cancer, there are still consequences of excessive or delayed treatment. By improving the sensitivity and specificity of circulating tumor cell (CTC) detection, a solution was proposed for differentiating benign from malignant pulmonary nodules. METHODS: In this study, we used telomerase reverse transcriptase–based (TERT-based) CTC detection (TBCD) to distinguish benign from malignant pulmonary nodules < 2 cm and compared this method with the pathological diagnosis as the gold standard. FlowSight and FISH were used to confirm the CTCs detected by TBCD. RESULTS: Our results suggest that CTCs based on TBCD can be used as independent biomarkers to distinguish benign from malignant nodules and are significantly superior to serum tumor markers. When the detection threshold was 1, the detection sensitivity and specificity of CTC diagnosis were 0.854 and 0.839, respectively. For pulmonary nodules ≤ 1 cm and 1–2 cm, the sensitivity and specificity of CTCs were both higher than 77%. Additionally, the diagnostic ability of CTC-assisted CT was compared by CT detection. The results show that CT combined with CTCs could significantly improve the differentiation ability of benign and malignant nodules in lung nodules < 2 cm and that the sensitivity and specificity could reach 0.899 and 0.839, respectively. CONCLUSION: TBCD can effectively diagnose pulmonary nodules and be used as an effective auxiliary diagnostic scheme for CT diagnosis. FUNDING: National Key Research and Development Project grant nos. 2019YFC1315700 and 2017YFC1308702, CAMS Initiative for Innovative Medicine grant no. 2017-I2M-1-005, and National Natural Science Foundation of China grant no. 81472013.